TY - JOUR
T1 - Association between type 2 diabetes and risk of cancer mortality
T2 - a pooled analysis of over 771,000 individuals in the Asia Cohort Consortium
AU - Chen, Yu
AU - Wu, Fen
AU - Saito, Eiko
AU - Lin, Yingsong
AU - Song, Minkyo
AU - Luu, Hung N.
AU - Gupta, Prakash C.
AU - Sawada, Norie
AU - Tamakoshi, Akiko
AU - Shu, Xiao Ou
AU - Koh, Woon Puay
AU - Xiang, Yong Bing
AU - Tomata, Yasutake
AU - Sugiyama, Kemmyo
AU - Park, Sue K.
AU - Matsuo, Keitaro
AU - Nagata, Chisato
AU - Sugawara, Yumi
AU - Qiao, You Lin
AU - You, San Lin
AU - Wang, Renwei
AU - Shin, Myung Hee
AU - Pan, Wen Harn
AU - Pednekar, Mangesh S.
AU - Tsugane, Shoichiro
AU - Cai, Hui
AU - Yuan, Jian Min
AU - Gao, Yu Tang
AU - Tsuji, Ichiro
AU - Kanemura, Seiki
AU - Ito, Hidemi
AU - Wada, Keiko
AU - Ahn, Yoon Ok
AU - Yoo, Keun Young
AU - Ahsan, Habibul
AU - Chia, Kee Seng
AU - Boffetta, Paolo
AU - Zheng, Wei
AU - Inoue, Manami
AU - Kang, Daehee
AU - Potter, John D.
N1 - Funding Information:
This work was supported by the US National Cancer Institute at the National Institutes of Health (R03CA150038) and by the Fred Hutchinson Cancer Research Center. The cohorts participating in the pooled analysis were supported by the following grants: Three-Prefecture Cohort Study Aichi (Japanese Ministry of the Environment); Japan Collaborative Cohort Study (National Cancer Center Research and Development Fund, Grant-in-Aid for Cancer Research; Grant for Health Services and Grant for Comprehensive Research on Cardiovascular and Life-Style Related Diseases from the Ministry of Health, Labour and Welfare, Japan; Grant for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology, Japan); Japan Public Health Center-Based Study 1 and 2 (National Cancer Center Research and Development Fund [23-A-31 (toku) and 26-A-2 (since 2011)]; Grant-in-Aid for Cancer Research from the Ministry of Health, Labour and Welfare, Japan [from 1989 to 2010]); Three-Prefecture Cohort Study Miyagi, Miyagi Cohort Study and Ohsaki National Health Insurance Beneficiaries Cohort Study (Grants-in-Aid for Cancer Research and for the Third Term Comprehensive Ten-Year Strategy for Cancer Control [H21-3jigan-ippan-003], Ministry of Health, Labour and Welfare, Japan); Takayama Study (National Cancer Center Research and Development Fund; National Heart, Lung, and Blood Institute [U01HL072507]; Chinese Academy of Medical Sciences); Shanghai Cohort Study (National Institutes of Health [R01CA144034, U01CA182876]); Shanghai Men’s Health Study and Shanghai Women’s Health Study (National Institutes of Health [R37CA070867, UM1CA182910, R01CA82729, UM1CA173640]); Community-Based Cancer Screening Program (National Science Council and Department of Health, Taiwan); Cardiovascular Disease Risk Factors Two-Township Study (Department of Health, Taiwan [DOH80-27, DOH81-021, DOH8202-1027, DOH83-TD-015 and DOH84-TD-006]); Korea Multicenter Cancer Cohort Study (Ministry of Education, Science and Technology, South Korea [2009-0087452]; National Research Foundation of Korea [2009-0087452]); Singapore Chinese Health Study (National Institutes of Health [R01CA144034, U01CA182876]); Health Effects of Arsenic Longitudinal Study (National Institutes of Health [P42ES010349, R01CA102484, R01CA107431]); Mumbai Cohort Study (International Agency for Research on Cancer, France; Clinical Trial Service Unit, UK; World Health Organization). The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Publisher Copyright:
© 2017, Springer-Verlag Berlin Heidelberg.
PY - 2017/6/1
Y1 - 2017/6/1
N2 - Aims/hypothesis: The aims of the study were to evaluate the association between type 2 diabetes and the risk of death from any cancer and specific cancers in East and South Asians. Methods: Pooled analyses were conducted of 19 prospective population-based cohorts included in the Asia Cohort Consortium, comprising data from 658,611 East Asians and 112,686 South Asians. HRs were used to compare individuals with diabetes at baseline with those without diabetes for the risk of death from any cancer and from site-specific cancers, including cancers of the oesophagus, stomach, colorectum, colon, rectum, liver, bile duct, pancreas, lung, breast, endometrium, cervix, ovary, prostate, bladder, kidney and thyroid, as well as lymphoma and leukaemia. Results: During a mean follow-up of 12.7 years, 37,343 cancer deaths (36,667 in East Asians and 676 in South Asians) were identified. Baseline diabetes status was statistically significantly associated with an increased risk of death from any cancer (HR 1.26; 95% CI 1.21, 1.31). Significant positive associations with diabetes were observed for cancers of the colorectum (HR 1.41; 95% CI 1.26, 1.57), liver (HR 2.05; 95% CI 1.77, 2.38), bile duct (HR 1.41; 95% CI 1.04, 1.92), gallbladder (HR 1.33; 95% CI 1.10, 1.61), pancreas (HR 1.53; 95% CI 1.32, 1.77), breast (HR 1.72; 95% CI 1.34, 2.19), endometrium (HR 2.73; 95% CI 1.53, 4.85), ovary (HR 1.60; 95% CI 1.06, 2.42), prostate (HR 1.41; 95% CI 1.09, 1.82), kidney (HR 1.84; 95% CI 1.28, 2.64) and thyroid (HR 1.99; 95% CI 1.03, 3.86), as well as lymphoma (HR 1.39; 95% CI 1.04, 1.86). Diabetes was not statistically significantly associated with the risk of death from leukaemia and cancers of the bladder, cervix, oesophagus, stomach and lung. Conclusions/interpretation: Diabetes was associated with a 26% increased risk of death from any cancer in Asians. The pattern of associations with specific cancers suggests the need for better control (prevention, detection, management) of the growing epidemic of diabetes (as well as obesity), in order to reduce cancer mortality.
AB - Aims/hypothesis: The aims of the study were to evaluate the association between type 2 diabetes and the risk of death from any cancer and specific cancers in East and South Asians. Methods: Pooled analyses were conducted of 19 prospective population-based cohorts included in the Asia Cohort Consortium, comprising data from 658,611 East Asians and 112,686 South Asians. HRs were used to compare individuals with diabetes at baseline with those without diabetes for the risk of death from any cancer and from site-specific cancers, including cancers of the oesophagus, stomach, colorectum, colon, rectum, liver, bile duct, pancreas, lung, breast, endometrium, cervix, ovary, prostate, bladder, kidney and thyroid, as well as lymphoma and leukaemia. Results: During a mean follow-up of 12.7 years, 37,343 cancer deaths (36,667 in East Asians and 676 in South Asians) were identified. Baseline diabetes status was statistically significantly associated with an increased risk of death from any cancer (HR 1.26; 95% CI 1.21, 1.31). Significant positive associations with diabetes were observed for cancers of the colorectum (HR 1.41; 95% CI 1.26, 1.57), liver (HR 2.05; 95% CI 1.77, 2.38), bile duct (HR 1.41; 95% CI 1.04, 1.92), gallbladder (HR 1.33; 95% CI 1.10, 1.61), pancreas (HR 1.53; 95% CI 1.32, 1.77), breast (HR 1.72; 95% CI 1.34, 2.19), endometrium (HR 2.73; 95% CI 1.53, 4.85), ovary (HR 1.60; 95% CI 1.06, 2.42), prostate (HR 1.41; 95% CI 1.09, 1.82), kidney (HR 1.84; 95% CI 1.28, 2.64) and thyroid (HR 1.99; 95% CI 1.03, 3.86), as well as lymphoma (HR 1.39; 95% CI 1.04, 1.86). Diabetes was not statistically significantly associated with the risk of death from leukaemia and cancers of the bladder, cervix, oesophagus, stomach and lung. Conclusions/interpretation: Diabetes was associated with a 26% increased risk of death from any cancer in Asians. The pattern of associations with specific cancers suggests the need for better control (prevention, detection, management) of the growing epidemic of diabetes (as well as obesity), in order to reduce cancer mortality.
KW - Asia Cohort Consortium
KW - Asians
KW - Cancer mortality
KW - Meta-analysis
KW - Type 2 diabetes
UR - http://www.scopus.com/inward/record.url?scp=85014523865&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85014523865&partnerID=8YFLogxK
U2 - 10.1007/s00125-017-4229-z
DO - 10.1007/s00125-017-4229-z
M3 - Article
C2 - 28265721
AN - SCOPUS:85014523865
SN - 0012-186X
VL - 60
SP - 1022
EP - 1032
JO - Diabetologia
JF - Diabetologia
IS - 6
ER -